Followers | 49 |
Posts | 11405 |
Boards Moderated | 0 |
Alias Born | 06/15/2014 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, January 09, 2024 9:16:34 AM
From what I understand the drug binds up phosphate to about the same degree as lanthanum carbonate but only takes up 1/4 of the volume hence making it easier for users (swallowing or less pills). If successful, they will still have a bit of an uphill road to squeeze into the market but with a market cap of only 32 m, and an indication that is quite large, they don't have to have much penetration to see their market cap quintuple at least.
Recent UNCY News
- Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference • GlobeNewswire Inc. • 07/11/2024 11:03:00 AM
- Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC) • GlobeNewswire Inc. • 07/10/2024 11:03:00 AM
- Unicycive Therapeutics Joins Russell Microcap® Index • GlobeNewswire Inc. • 07/01/2024 11:03:00 AM
- Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial • GlobeNewswire Inc. • 06/25/2024 11:30:00 AM
- Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress • GlobeNewswire Inc. • 05/28/2024 11:03:00 AM
- Unicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor Conference • GlobeNewswire Inc. • 05/23/2024 11:03:00 AM
- Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting • GlobeNewswire Inc. • 05/15/2024 11:03:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 08:28:00 PM
- Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/13/2024 08:16:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 08:06:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/08/2024 08:05:39 PM
- Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/10/2024 11:03:00 AM
- Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/28/2024 08:15:00 PM
- Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress • GlobeNewswire Inc. • 03/25/2024 11:03:00 AM
- Unicycive Announces $50 Million Private Placement • GlobeNewswire Inc. • 03/14/2024 11:03:00 AM
- Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference • GlobeNewswire Inc. • 03/13/2024 11:03:00 AM
- Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) • GlobeNewswire Inc. • 03/07/2024 09:12:00 PM
- Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients • GlobeNewswire Inc. • 03/04/2024 12:03:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 09:06:09 PM
- Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting • GlobeNewswire Inc. • 02/14/2024 12:03:00 PM
- Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference • GlobeNewswire Inc. • 01/29/2024 12:03:00 PM
- Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones • GlobeNewswire Inc. • 01/23/2024 12:03:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/22/2024 09:27:47 PM
- Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis • GlobeNewswire Inc. • 12/18/2023 12:03:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 12/08/2023 09:36:22 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM